Milestone positions Adalvo as a global leader in one of the world's largest and fastest-growing markets for GLP-1 therapies, with Sandoz as commercial partner.
Adalvo, one of Europe's leading B2B pharmaceutical companies specialising in dossier development and out-licensing, today announces it has received Marketing Authorisation (MA) from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA) for semaglutide - joining the first wave of companies to achieve regulatory approval.
The approval grants Adalvo the authority to commercialise semaglutide in Brazil, one of the largest pharmaceutical markets in Latin America and a region experiencing significant growth in demand for GLP-1-based therapies, with the global semaglutide market valued at $34.5 Bn in 2025.
Adalvo has partnered with Sandoz, a global leader in generic and biosimilar medicines, as its commercial partner for Brazil. Together, the two companies are positioned to bring an accessible, high-quality semaglutide option to Brazilian patients and healthcare providers.
"This approval is a defining moment for Adalvo and reflects years of investment in regulatory excellence and strategic market positioning. Brazil is a critical market, and being among the first to achieve this authorisation demonstrates our capability to move at speed and scale. We look forward to working with Sandoz to deliver genuine value to patients across Brazil."
This milestone is the latest in Adalvo's expanding presence in the GLP-1 and metabolic therapy space. The company has been building a portfolio of semaglutide dossiers across multiple high-priority global markets, reflecting a deliberate strategy to lead in one of the most commercially significant therapeutic areas of the decade.
Operating across 140+ markets with a network of 170+ commercial partners, Adalvo's model — developing world-class dossiers and out-licensing to best-in-class regional partners — is designed to bring innovative generics to market at speed and scale.
To add semaglutide to your portfolio, contact the team today.